2023
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
Kristensen L, Strober B, Poddubnyy D, Leung Y, Jo H, Kwok K, Vranic I, Fleishaker D, Fallon L, Yndestad A, Gladman D. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib. Therapeutic Advances In Musculoskeletal Disease 2023, 15: 1759720x221149965. PMID: 36777695, PMCID: PMC9909057, DOI: 10.1177/1759720x221149965.Peer-Reviewed Original ResearchMajor adverse cardiovascular eventsAtherosclerotic CV diseaseTofacitinib-treated patientsAdverse cardiovascular eventsCV diseaseASCVD riskHigh blood pressurePsoriatic arthritisHigh riskHeart-related problemsHigher baselineCardiovascular eventsBlood pressureRisk calculatorIncidence rateMore casesBaseline cardiovascular riskBaseline metabolic syndromeCardiovascular disease riskJanus kinase inhibitorDose of tofacitinibGroup of conditionsBaseline MetSPsA trialsTofacitinib exposure
2022
OP0027 ASSOCIATION BETWEEN BASELINE CARDIOVASCULAR RISK AND INCIDENCE RATES OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MALIGNANCIES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS RECEIVING TOFACITINIB
Kristensen L, Strober B, Poddubnyy D, Leung Y, Jo H, Kwok K, Vranic I, Fleishaker D, Fallon L, Yndestad A, Gladman D. OP0027 ASSOCIATION BETWEEN BASELINE CARDIOVASCULAR RISK AND INCIDENCE RATES OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MALIGNANCIES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS RECEIVING TOFACITINIB. Annals Of The Rheumatic Diseases 2022, 81: 20-20. DOI: 10.1136/annrheumdis-2022-eular.1762.Peer-Reviewed Original ResearchMajor adverse CV eventsASCVD riskCV riskIncidence rateBristol-Myers SquibbGrant/research supportPfizer IncPsoriatic arthritisSpeakers bureauEli LillyMajor adverse cardiovascular eventsRisk categoriesGilead SciencesASCVD risk categoryBaseline cardiovascular riskBaseline CV riskTofacitinib-treated patientsTreatment of PsAAdverse cardiovascular eventsAdverse CV eventsCV disease riskCoronary artery diseaseHigh incidence rateDose of tofacitinibCV events